India, Nov. 26 -- SMS Pharmaceuticals announced that its associate company, VKT Pharma, has received approval from the US FDA for its reformulated Ranitidine tablets in 150 mg and 300 mg strengths. This clearance marks the medication's return to the US market after five years.
The approval follows extensive safety testing and enhanced manufacturing processes designed to address earlier concerns about NDMA impurity formation. With this re-entry, patient access to the acid-reducing drug is expected to improve, benefiting individuals who depend on it for various gastrointestinal conditions.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....